Radiotherapy in Combination With Pembrolizumab in Patients With PSA Persistence or Biochemical Recurrence After Radical Prostatectomy Due to Prostate Cancer
Latest Information Update: 22 Aug 2024
Price :
$35 *
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms Pembro-SRT
- 03 Mar 2023 Last checked against Clinicaltrials.gov record.
- 07 Jul 2022 Status changed from not yet recruiting to recruiting.
- 19 Feb 2022 Study design presented at the 2022 Genitourinary Cancers Symposium